Abstract
The reverse-transcription loop-mediated isothermal amplification (RT-LAMP) is a cheaper and faster testing alternative for detecting SARS-CoV-2. However, high false-positive rate due to misamplification is one of the major limitations. To overcome misamplifications, we developed colorimetric and fluorometric RT-LAMP assays. The assay performances was verified by the gold-standard RT-qPCR technique on 150 clinical samples. Compared to other primer sets with six primers (N, S, and RdRp), E-ID1 primer set, including five primers, performed superbly on both colorimetric and fluorometric assays, yielding sensitivities of 89.5% and 100%, respectively, with a limit of detection of 20 copies/µL. The colorimetric RT-LAMP had a specificity of 97.2% and an accuracy of 94.5%, while the fluorometric RT-LAMP obtained 96.9% and 98%, respectively. No misamplification was evident even after 120 minutes, which is crucial for the success of this technique. These findings are important to support the use of RT-LAMP in the healthcare systems in fighting COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study is funded by Institute for Research and Medical Consultations (IRMC) under the project number 2020-IRMC-S-3 and the Deanship of Scientific Research (DSR) of Imam Abdulrahman Bin Faisal University (IAU) Fast track fund of COVID-19 (COVID19-2020-026-IRMC). Huseyin Tombuloglu received the awards.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Review Board (IRB) at Imam Abdulrahman bin Faisal University (IAU), with IRB number IRB-2020-13-406. All methods were carried out in accordance with current guidelines and regulations. De-identified samples left over after completion of diagnostic tests were used; hence, this study requires no consenting, as per institutional ethics committee regulations and informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Statements and Declarations
Ethical approval. The study was approved by the Institutional Review Board (IRB) at Imam Abdulrahman bin Faisal University (IAU), with IRB number IRB-2020-13-406. All methods were carried out in accordance with current guidelines and regulations. De-identified samples left over after completion of diagnostic tests were used; hence, this study requires no consenting, as per institutional ethics committee regulations and informed consent.
Competing interests The authors have declared that no competing interests exist.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
